Testing a supplement to reduce early psychosis symptoms

This trial is testing whether N-acetylcysteine, a supplement available over the counter, can help reduce early psychosis symptoms in people at clinical high risk for schizophrenia. The study will also measure how the medication affects brain activity patterns related to how the brain processes sounds and word meanings. Researchers believe this treatment might prevent the onset of more serious psychotic illness.

People sometimes experience early warning signs of psychosis before developing schizophrenia. This medication has shown promise in other research, and this trial will test whether it can help reduce these early symptoms and improve brain function—potentially preventing the condition from progressing.